Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 387

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial1

Open access
WALLER, D, PEAKE, M, STEPHENS, R, GOWER, N, MILROY, R, PARMAR, M, RUDD, R, SPIRO, S, ONBEHALFOFALLBLTPARTICIPANTS · 2004 · European Journal of Cardio-Thoracic Surgery

Abstract

OBJECTIVES: The non-small cell lung cancer (NSCLC) meta-analysis suggested a survival benefit for cisplatin-based chemotherapy when given in addition to surgery, radical radiotherapy or 'best supportive care'. However, it included many small trials and trials with differing eligibility criteria and chemotherapy regimens. The aim of the Big Lung Trial was therefore to run a large pragmatic trial to confirm the survival benefits seen in the meta-analysis. METHODS: In the surgery setting, a total of 381 patients were randomised to chemotherapy (C, 192 patients) or no chemotherapy (NoC, 189 patients). C was three 3-weekly cycles of cisplatin/vindesine, mitomycin/ifosfamide/cisplatin, mitomycin/vinblastine/cisplatin or vinorelbine/cisplatin. RESULTS: Chemotherapy was given before surgery in 3% of patients whilst 97% received adjuvant chemotherapy. Baseline characteristics were: median age 61 years, 69% male, 48% squamous cell, 93% WHO PS 0-1, 27% stage I, 38% stage II, and 34% stage III. Complete resection was achieved in approximately 95% of patients. In the C group, 13% received no chemotherapy, 21% one or two cycles, and 64% all three cycles of their prescribed chemotherapy (60% of the latter with no delays or modification). 30% had grade 3/4 toxicity, mainly haematological, nausea/vomiting and neutropenic fever, and six patients were reported as having a treatment-related death. 198 (52%) of patients have died, but there is currently no evidence of a benefit in overall survival to the C group: HR 1.02 (95% CI 0.77-1.35), P = 0.90). CONCLUSIONS: This trial has failed to observe a survival benefit with adjuvant chemotherapy following complete resection of stage I-III NSCLC. However, the hazard ratio and 95% confidence intervals are consistent with the previously reported meta-analysis and two large recently reported trials, which suggest a small survival benefit with cisplatin-based chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejcts.2004.03.041

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 387

Metadata

Authors
WALLER, D., PEAKE, M., STEPHENS, R., GOWER, N., MILROY, R., PARMAR, M., RUDD, R., SPIRO, S., & ONBEHALFOFALLBLTPARTICIPANTS
Venue
European Journal of Cardio-Thoracic Surgery
Published
2004-07
Volume
26
Issue
1
Pages
173-182
ISSN
1010-7940 (ISSN-L)
OpenAlex
W2025577038
Cited by
387
References
4
FWCI
23.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial1. https://app.cochat.ai/papers/10.1016/j.ejcts.2004.03.041
The paper
WALLER, D., PEAKE, M., STEPHENS, R., GOWER, N., MILROY, R., PARMAR, M., RUDD, R., SPIRO, S., & ONBEHALFOFALLBLTPARTICIPANTS. (2004). Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial1. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1016/j.ejcts.2004.03.041

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.